Jose Sandoval S, MD FACP 🇨🇴🇨🇴

After the HUGE success of the 1st National #ICE_T Conference in Orlando 🎉🧊… 🔥 3 BIG ANNOUNCEMENTS incoming — starting with: 1/ The 2nd Regional #ICE_T Conference is headed to Kansas City, KS 🏙️ 📍 Hosted by @KUcancercenter 🗓️ Sept 27–28 ⏳ The countdown begins NOW! #ICE_T…

Now presenting Rebecca Gonzalez PharmD @MoffittNews “Navigating the Challenges: Managing Adverse Effects of Cellular Therapies in ALL” National #ICE_T #mmsm #MedEd #myeloma #MedTwitter #USMIRC @USMIRCNEWS @OncoAlert #سرطان_الدم #المايلوما @CancerNetwrk

Our @FLASCO_ORG "Breaking Barriers" Conference is coming this November again! we are addressing topics to improve cancer care in Veterans, rural communities, minorities and other disadvantage populations with @Latinamd @BrainTumorDoc @EugeneManley @MikeCusnir @BlasePolite from…

Excellent Panel discussion of the Lymphoma session many thanks to Dr. Marc Hoffmann, @HemSandoval @SagheerTiba Dr. Forat Lutfi @NausheenAhmedMD @kczmj #ICE_T #mmsm #MedEd #myeloma #MedTwitter #USMIRC @USMIRCNEWS @OncoAlert #سرطان_الدم #المايلوما @CancerNetwrk

Thank you to @HemSandoval for speaking to us about the CAR T revolution in lymphoma and the need to expand access to this treatment modality! #ICE_T | @FLASCO_ORG

Now presenting @HemSandoval “Revolutinizing Lymphoma Treatment: The latest Breakthrough in CAR-T therapy” National #ICE_T #MedEd #MedTwitter #USMIRC @USMIRCNEWS @OncoAlert #سرطان_الدم #المايلوما @CancerNetwrk

⏳2 days left for the 1st National ICE-T meeting #mmsm #USMIRC @OncoAlert @oncodaily @NausheenAhmedMD @HemSandoval @mshahzadmd @mumairmushtaq @kczmj @anup_kasi @AtrashShebli @medicalwatchBC @Larvol eeds.com/portal_live_ev…

Hoy comienza la III Jornada GCEL! Evento presencial y virtual donde nos reuniremos a discutir de linfoma junto con el @Grupo_GELL @GUruguayLinfoma @GLinfoma Inscripciones virtuales: lnkd.in/eK4HdgHT

God bless you Ozzy.

Ozzy Osbourne has sadly passed away at the age of 76.

Ozzy Osbourne has passed away at the age of 76

Ozzy Osbourne has sadly passed away at the age of 76.

Bispecifics in R/R LBCL @BloodPortfolio: - 245 pts, 64% epcor, 60% prior CAR - mPFS 2.5 mos (!!!): 2.3 epcor, 3.8 glofi - mOS 7.8 mos overall (in MV model, glofi = better OS) - worse PFS/OS if trial ineligible & w/i 90 d of CAR Outcomes not great. #lymsm ashpublications.org/blood/article/…

businesswire.com/news/home/2025…. Looks like Glofi-GemOX is a no go from the FDA standpoint. @JulioChavezMD @lymphomaphilia @JuanAlderuccio @bshah @iHematologo @GuiperiniMD @KrishPatelMD. Was there any hope left s/p ODAC?

With a high rate of ≥grade 3 toxicities, Is BrECADD better than Nivo AVD in elderly patients with advanced Hodgkin lymphoma? >>>PET–Guided BrECADD in Older Patients With Advanced-Stage Classic HL ascopubs.org/doi/10.1200/JC…

Friday night fever 🎉 have a good weekend friends ✌️#MindEnterprises #Campari #MontBlanc

Absolutely agree with every single point. It think in rare diseases such as T cell #lymphoma #lymsm is worse! Also, if you are in a mid size institution at a public hospital system is way way harder! We need to fix this now and we love to think about solutions.

Why do many regulatory oncology phase III trials not accrue sufficient US patients? This issue came up repeatedly at today’s ODAC for belantamab for myeloma. And I can address it at least for myeloma. 1) In our healthcare system, opening a trial in a timely manner is a…

Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China ashpublications.org/blood/article-… The Ru-D regimen was well tolerated, resulting in OS rates of 85.7%, 67.9%, and 53.6% at 2 months, 6 months, and 2 years,…